about
Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysisHuman recombinant activated protein C for severe sepsisIncreased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugsAlleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory DrugsBiology-inspired microphysiological system approaches to solve the prediction dilemma of substance testingEffects of laterally wedged insoles on symptoms and disease progression in medial knee osteoarthritis: a protocol for a randomised, double-blind, placebo controlled trial.The effects of hip muscle strengthening on knee load, pain, and function in people with knee osteoarthritis: a protocol for a randomised, single-blind controlled trial.Preventive Health Perspective in Sports Medicine: The Trend at the Use of Medications and Nutritional Supplements during 5 Years Period between 2003 and 2008 in FootballLessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures.Governance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness NetworkThe effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in ScotlandNon-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trialsWhat therapies have replaced rofecoxib in Ireland?Life after Vioxx: the clinical implications.Correlation between Drug Market Withdrawals and Socioeconomic, Health, and Welfare Indicators WorldwideA methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer.The use of medication and nutritional supplements during FIFA World Cups 2002 and 2006.Ethics, industry, and outcomes.Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological studyThe use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.Educational Paper: Aspects of clinical pharmacology in children--pharmacovigilance and safety.Celecoxib, a COX-2 inhibitor, synergistically potentiates the anti-inflammatory activity of docosahexaenoic acid in macrophage cell line.Patients with drug reactions -- is it worth testing?Catalytic asymmetric synthesis using feedstocks: an enantioselective route to 2-arylpropionic acids and 1-arylethyl amines via hydrovinylation of vinyl arenesAnalysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten.Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs.Sentinel systems are needed for long term adverse drug reactions.The ethics of changing practice: do we cross the line?Safety of new medicines in young children.COX 2 inhibitors, traditional NSAIDs, and the heart.Ototopical neomycin exposure in children with nonintact tympanic membranes.Illicit Internet availability of drugs subject to recall and patient safety consequences.What if Derek Willoughby were right? Cyclo-oxygenase is an anti-inflammatory enzyme.Differential anti-inflammatory and chondroprotective effects of simulated digests of indomethacin and an herbal composite (Mobility) in a cartilage explant model of articular inflammation.Pharmacovigilance in developing countries (part I): importance and challenges.Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.NSAID hypersensitivity – recommendations for diagnostic work up and patient management.Raging the War Against Inflammation With Natural Products
P2860
Q21146683-E7F5A5FC-08AA-4752-9375-51F04F651D42Q24242859-C16B8337-12C2-4967-8633-A5340C38788DQ28218432-D3B55D4D-49EB-4722-9DC8-2CD8699C75AEQ30234292-49253F62-E285-4E37-864B-1254D31BA3CAQ30358385-E27A603E-317B-4AB3-A9ED-11A4D0C0DDF5Q33300151-BD9749C3-FB3C-468D-9116-D6EBC0FD5AEDQ33309347-5DBB2FB7-3E04-4354-AD29-E7DEEF7A605EQ33974462-88A2BD93-A0E8-42EB-A69E-B339D19342A2Q34138798-F10668C6-7385-4563-BBC4-82708E14C3EBQ35049886-4ED6CC07-489D-4396-9678-7682AD4910DAQ35827761-B546B09D-4EA9-42AB-8035-0D1227B46546Q35961855-2DCE8A96-521C-4914-8D1B-8CE68822D384Q36102610-AEA8B311-D220-457E-828B-25BCD08D90E1Q36141793-276AE78F-C216-4996-884B-32538A1AFF29Q36241692-782B0FC8-FC52-4523-9405-67389B4211BCQ36386030-77C2AC92-66FE-46E1-9A85-B960022D97A8Q36971117-97E4A9A0-4080-474D-A2DA-5B9B78A9C045Q37143672-98E204EC-F221-4253-A33B-6F398A37B7DEQ37471109-094D7856-016D-4B4B-ABD2-7CA4C9B19605Q37475646-3F30F9C4-8036-4924-8D91-29FD9E0F983FQ38056655-D6D12C1A-C058-4BB0-9E69-8DCBDC02C9EBQ38787940-3FE57E37-430B-4CB5-B94E-4133D0544B04Q40303852-CAAA4F4E-BAE3-4E05-A394-4FE2759657BAQ41873450-D678F607-BC09-4F1B-8F54-40220CDC1CD8Q42032807-C7884F5D-E3B0-41F4-A0B6-1CF6745A79D2Q42497204-8B9C0C04-9B46-4692-A4D5-F1820F52D073Q42498404-7C0C20A1-E02E-4089-8803-12C85D162EEEQ42741589-5B551925-23EA-4C12-85AA-CA0D0737EB92Q42926653-61BC7142-6BB9-4BDB-B2DF-6116A3D3D168Q42945232-5E63B7FD-6B29-4A1D-81AA-11C6024AD2ACQ43062432-D9AF887F-7362-47FF-A8EF-9DB9ED10EF0EQ44565106-862DC4A3-DD59-4C9B-A839-9C3C9A574782Q46556031-D7B97EF9-1190-4978-A3CC-607A8AE9F463Q46783129-D9648AB5-3725-4A33-A486-6D8A0B16D115Q46908588-13A91451-C07E-4D8E-B255-D7A58CE51A82Q48105245-4567D4EF-664D-4F65-89D8-A527F582FBE7Q54920356-6DDF23CF-2966-42BB-AF39-FAB49EE59651Q55423435-A054566A-1D91-4564-A764-15A4DF5EA392Q58758818-A24A4566-7F4C-4431-9C3F-14BF3643490E
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Lessons from the withdrawal of rofecoxib.
@en
Lessons from the withdrawal of rofecoxib.
@nl
type
label
Lessons from the withdrawal of rofecoxib.
@en
Lessons from the withdrawal of rofecoxib.
@nl
prefLabel
Lessons from the withdrawal of rofecoxib.
@en
Lessons from the withdrawal of rofecoxib.
@nl
P2093
P2860
P356
P1433
P1476
Lessons from the withdrawal of rofecoxib.
@en
P2093
Paul A Dieppe
Richard M Martin
Shah Ebrahim
P2860
P304
P356
10.1136/BMJ.329.7471.867
P407
P50
P577
2004-10-01T00:00:00Z